Aditxt Inc. is a biotech company headquartered in San Francisco, California, that focuses on developing and commercializing innovative technologies for immune monitoring and diagnostics. The company was founded in 2018 with a vision to revolutionize healthcare by providing personalized immune monitoring solutions.
Aditxt's core technology is called AditxtScore™, which is a proprietary platform that assesses an individual's immune system's health. This platform combines data from multiple sources, such as gene expression, cellular analysis, and clinical information, to generate a comprehensive immune health profile. The goal is to use this information to better understand a person's immune response and potentially predict or diagnose diseases more accurately.
The company aims to apply its AditxtScore™ platform to a wide range of applications, including cancer diagnostics, infectious diseases, autoimmune disorders, and other immune-related conditions. Their technology has the potential to impact patient care and outcomes by enabling earlier and more precise disease detection and monitoring.
In addition to their proprietary technology, Aditxt has been actively pursuing strategic partnerships and collaborations with other healthcare companies and research institutions. These collaborations enable them to further validate and refine their technology and explore new applications and markets.
Aditxt's commitment to advancing healthcare through innovation and technology is evident in their continued research and development efforts. They are dedicated to making a meaningful impact in the field of immune monitoring and diagnostics, ultimately contributing to better health outcomes for patients worldwide.